Torisel (temsirolimus)
by Jessica Langholtz
Updated: Dec 3, 2009
Updated: Dec 3, 2009
| Brand Name: | Torisel |
| Generic Name: | temsirolimus |
| Code Name: | |
| Company: | Pfizer |
| FDA Clinical Phase: | 1/2 |
Description:
Torisel, which is currently approved for treatment of advanced renal cell carcinoma, is being studied for treatment of multiple myeloma in combination with Velcade (bortezomib) and dexamethasone (Decadron). Torisel inhibits the mammalian target of rapamycin (mTOR), which is a critical protein for cancer cell growth.
Clinical Trials:
For a list of clinical trials studying Torisel for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for Torisel: http://www.torisel.com/
Related Articles:
- Getting To Know: Tiragolumab
- Getting To Know: TNB-383B
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma